Research priorities during infectious disease emergencies in West Africa. by Folayan, Morenike Oluwatoyin et al.
Folayan et al. BMC Res Notes  (2018) 11:159  
https://doi.org/10.1186/s13104-018-3263-3
RESEARCH NOTE
Research priorities during infectious 
disease emergencies in West Africa
Morenike Oluwatoyin Folayan1* , Bridget Haire2, Dan Allman3, Aminu Yakubu4 and Muhammed O. Afolabi5
Abstract 
Objectives: This paper presents the results of the consultations conducted with various stakeholders in Africa and 
other experts to document community perspectives on the types of research to be prioritised in outbreak conditions. 
The Delphi method was used to distill consensus.
Results: Our consultations highlighted as key, the notion that in an infectious disease outbreak situation, the need to 
establish an evidence base on how to reduce morbidity and mortality in real time takes precedence over the pro‑
duction of generalizable knowledge. Research studies that foster understanding of how disease transmission could 
be prevented in the future remain important, implementation research that explores how to mitigate the impact 
of outbreaks in the present should be prioritized. Clinical trials aiming to establish the safety profile of therapeutic 
interventions should be limited during the acute phase of an epidemic with high fatality—and should preferably use 
adaptive designs. We concluded that community members have valuable perspectives to share about research priori‑
ties during infectious disease emergencies. Well designed consultative processes could help identify these opinions.
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Introduction
The scale, duration and magnitude of human suffering 
experienced and witnessed during the recent West Afri-
can Ebola epidemic had considerable impact on how 
infectious disease emergency responses are framed. 
Several trials to find candidate drugs to treat and vac-
cines to prevent Ebola were conducted as a result of this 
epidemic. However, none of the candidate drugs were 
found to have the required efficacy for treatment; and 
only one of the vaccine trials produced results pointing 
towards effectiveness against Ebola Virus Disease (EVD) 
[1]. An important lesson learnt, however, was that trials 
that meet internationally accepted standards can be con-
ducted during disease outbreaks including those caused 
by high-hazard pathogens [1]. However, these studies had 
some contentious elements.
From a research ethics perspective, there are concerns 
about the social value of conducting research in such 
situations considering the high mortality and morbidity 
associated with EVD [2, 3]. The concerns relate to the 
social value of conducting such studies during a highly 
fatal infectious disease epidemic. Together, these con-
cerns ignited debates on the justification for the conduct 
of randomised placebo-controlled trials (RCTs), prioriti-
sation of resources, compassionate access to unapproved 
therapies, and the balancing of research and public health 
action [4–6]. Responding to these concerns, several arti-
cles were written including normative commentaries [7], 
empirical research [8]; and substantive guidance docu-
ments were developed [9–12] by researchers and pub-
lic health practitioners alike. Researchers also discussed 
how the weak healthcare systems, inadequate health-
care resources, and the histories of civil war and politi-
cal violence affected the epidemic responses [13]; and 
the impact of these on the choice of clinical trial design 
[4]. The challenge of providing appropriate ethics review 
and oversight to ensure ethical conducted of the studies 
in the region, under these circumstances, was also high-
lighted [14, 15].
Our work aimed to contribute to the discourses and 
efforts at addressing concerns of conducting research 
studies in disease outbreak situations. Overall, our focus 
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is to develop a community engagement framework that 
draws both on the perspectives, empirical findings and 
guidelines developed so far, coupled with the experi-
ence of stakeholders who lived through the epidemic. In 
this paper, as part of our overarching work, we present 
community perspectives on clinical trial design and how 
these might inform future research during outbreaks. We 
report on the outcome of an extensive consultative pro-
cess with experts in bioethics, community engagement, 
and research—including those involved with Ebola clini-
cal trials in West Africa—social scientists and members 
of ethics committees in West Africa. The key outcome of 
this consultation was a consensus statement on research 
priorities and appropriate clinical trial designs during 
such epidemics.
Main text
The consultative process used the Delphi method to 
reach a consensus [16–19]. It allowed for a group process 
that involves a series of iterative interactions with experts 
on a complex issue of interest to various stakeholders—
bioethicists, social scientists, ethics committee members 
and community members—with no history of conclu-
sive decisions. The Delphi technique had been used in 
the past to reach consensus about issues related to rand-
omized controlled trial design [20, 21].
There were three phases of iterations and an addi-
tional round of iteration each for phases I and II. Phase 
I involved a face-to-face consultation with eight research 
experts, bioethicists and community engagement special-
ists to answer four research questions. Phase II involved 
a review of the document developed in Phase 1 by three 
experts—a bioethicist, a researcher involved with clini-
cal trials for Ebola vaccine evaluation in West Africa, 
and a researcher working on community engagement 
issues in Africa. A second iteration included these three 
experts and the eight experts involved with Phase I. A 
consensus document was developed which included only 
issues where consensus was reached. Phase III involved 
consultative discussions on the consensus document 
developed in phase II with 20 members of the Network 
of Ethics Committee members in West Africa. They (dis)
agreed with the statements in the consensus document, 
and discussed their views during a plenary session. MOF 
collated and analysed the themes and sub-themes that 
emerged from all the iterations (see Additional file 1).
Research priorities
Participants that took part in the consultations pos-
ited that during an infectious disease outbreak, research 
studies that focus on mitigating suffering in the present 
and those that seek to identify means of prevention in 
future epidemics are those that need to be prioritised. 
Where there are various unknowns and uncertainties 
about the utility of existing medications and the existing 
clinical care pathways and systems to cope with an epi-
demic, implementation research should be prioritized 
during the acute phase of an epidemic with high fatality. 
Implementation research was understood as research to 
explore improved or novel ways to address disease condi-
tions including clinical care pathways and health systems 
challenges that would provide affected persons with the 
best chances of survival. While undertaking any of these 
research studies, participants argued that researchers 
should use designs that increase the prospect of includ-
ing affected populations as study participants. However, 
while included in such studies, the ideal design should 
also make it possible for the participants to access ther-
apy (with known or unknown efficacy, when or where 
available).
Participants noted that even in an emergency dis-
ease outbreak, the act of research alone could not be 
construed as an emergency undertaking. It could be 
valuable, arguably even necessary, but could not be con-
stituted as an emergency per se. Thus, unless the purpose 
is to determine the efficacy or effectiveness of a clinical 
response to an intervention including drugs with a sig-
nificant likelihood to benefit patients, clinical trial stud-
ies need not be a priority during the acute phase of an 
infectious disease epidemic with high mortality and 
morbidity. Limiting clinical trials in this manner would 
avoid distraction from optimal use of limited resources—
human especially—that should otherwise be invested in 
the public health response. In effect, in the acute phase 
of the infection, phase II and III drug trials could be pri-
oritized over those that aim to establish the safety profile 
of therapeutic interventions (phase I studies). Clinical tri-
als that do not diminish the prospect for morbidity and 
mortality arising from the infectious disease emergency 
should not be prioritized.
Research designs
The consensus of opinions during the consultative pro-
cess was that research conducted during a self-limiting 
infectious disease epidemic should be designed in a way 
that is flexible enough to address immediate community 
needs of decreasing mortality and morbidity. Participants 
argued for the use of adaptive trial designs [22] to test 
interventions, in order to increase the prospect of mak-
ing timely changes to trial designs, as may be required. 
Where there is a public health response that supports 
the compassionate use of research products, the research 
design should not exclude the use of such drugs.
Participants had strong views about equity of access to 
potentially useful interventions, even where such inter-
ventions are not proven to be safe and effective. Where an 
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epidemic affects children and pregnant women, clinical 
trials should be planned in a cascaded fashion that allows 
for the recruitment of children and pregnant women 
during different waves of the trials. This way, as data on 
safety becomes available, enrolment of these populations 
with particular vulnerabilities can be considered. In order 
to facilitate this, research teams should consider inclu-
sion of children and pregnant women in research studies 
early during the research concept development stage.
During infectious disease outbreaks, the main moti-
vating factor for research participation is not altruism. 
Altruism—the decision to enrol simply for the benefit of 
others—has been documented as one of the top motiva-
tions for participation in research studies in other con-
texts. However, participants from our consultations held 
that where there is intense fear and uncertainty as in the 
case of the Ebola epidemic, people choose to participate 
in research as a health-related resource-seeking strategy. 
Individuals who volunteer as research participants during 
infectious disease emergencies with high morbidity and 
mortality, with little or no prospect for research-related 
benefits, may assume that the State would take care of 
their needs in the face of any eventualities. Researchers 
need to recognise these realities of the lives of study par-
ticipants, and work with appropriate authorities—com-
munity members and research ethics committees—to 
define appropriate compensation including insurance 
cover for research participation in these situations.
Discussion
Participants believe that in an infectious disease out-
break, the need to produce generalizable knowledge is 
subordinate to the need to establish evidence on how to 
reduce morbidity and mortality in real time. While con-
ducting research that would have a greater benefit in the 
future was seen as important, it was less so than provid-
ing a robust response to patient care and outbreak con-
trol during an on-going infectious disease epidemic. This 
was why participants felt that where clinical trials are 
considered for implementation during an outbreak, adap-
tive trial designs should be prioritised. This would allow 
for modifications of the trial and/or statistical procedures 
of the  trial  after its initiation without undermining its 
validity and integrity. It could permit liberalised access 
to unlicensed drugs through compassionate access; and 
accommodate inclusion criteria that prioritise the broad-
est access for those at risk.
This view—prioritising amelioration of suffering in the 
present over saving future putative lives—contrasts with 
argument put forward by Eyal and Lipsitch [23], that tra-
ditional RCTs should be prioritized because they could 
save more lives in the longer term by virtue of the greater 
certainty they provide about an intervention’s level of 
efficacy. Doussau and Grady [24] in their critique of the 
‘stepped wedge design’ had opined that hope is a poor 
basis for science albeit in an attempt to argue against the 
potential of the design to allow participants receive the 
intervention at some point. Our findings however sug-
gest that hope might be an important community value 
that could help foster and maintain support for clinical 
research and public health interventions during an epi-
demic of crisis proportions.
Considerations for ensuring timely data generation 
for women and children through the cascading of clini-
cal trial findings that fast-track their recruitment, may be 
suggestive of the need to review current ethical guide-
lines on recruitment of women and children in clinical 
trials specifically during emergency outbreaks. While a 
Delphi consultation may not provide sufficient evidence 
to justify this major change in current recruitment prac-
tices for clinical trials, this finding should inform on-
going deliberations on alternative clinical trial designs 
conducted during emergencies.
Also, the principle of reciprocity [25] requires that 
communities hosting research should be left with long-
term research associated benefits where feasible. Invest-
ing resources and prioritising research that results in 
the development of appropriate and effective supportive 
packages of careduring infectious disease outbreaks is 
a way to ensure communities are left better off after the 
conduct of the research. Infected and affected people may 
receive immediate benefits from intervention research; 
and future patients will also benefit from the research 
outcomes. During the last Ebola epidemic, not enough 
was learnt about the true benefits (or potential harms) of 
administering specific supportive care packages appro-
priate for resource-limited settings [1, 26, 27]. Rigorous 
reviews of existing data in order to codify a decent, evi-
dence based standard of care are urgently required.
Limitations
The use of Delphi as a consultative method has the risk 
of discussants reaching a compromised consensus with 
some of the points of dissent and contention, and the 
reasoning behind these getting lost [16]. The consensus 
reached are also based on the constructed reality of the 
experts consulted thereby limiting its fit into the tradi-
tional reliability and validity criteria [19]. The process 
however helped us identify some of the common val-
ues held by those consulted. Also, discussions about 
study designs included perspectives of lay-persons 
who had limited expertise and experience with clinical 
trial design. It is possible that if trained scientists were 
involved in the consultation, the discussions on appro-
priate research design may have been broader. Further, 
our participants were willing to support in theory, 
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increased risks with regard to earlier participation by 
pregnant women and children rather than exclusion, a 
perspective that challenges current ethical norms; and 
might be defensible with respect to an outbreak as dev-
astating as Ebola. This risk tolerance might change with 
less deadly epidemics.
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